The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.
Merck & Co., Inc. is aiming to take new approaches to tackle Alzheimer’s disease through a partnership with Cerevance Inc. worth $25m upfront.
The partners will use Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology to identify novel targets for Alzheimer's. The Boston, MA-headquartered biotech will also concurrently out-license an undisclosed discovery-stage program to Merck
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
An ‘historic economic prosperity deal’ does not include the sector.
